Abstract
BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.
| Language | English (US) |
|---|---|
| Pages | 639-646 |
| Number of pages | 8 |
| Journal | Prostate |
| Volume | 77 |
| Issue number | 6 |
| DOIs | |
| State | Published - May 1 2017 |
| Externally published | Yes |
Fingerprint
Keywords
- abiraterone
- advanced prostate cancer
- castrate-resistant
- enzalutamide
ASJC Scopus subject areas
- Oncology
- Urology
Cite this
Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer : An Indirect Comparison. / Chopra, Akhil; Georgieva, Mina; Lopes, Gilberto; Yeo, Chong Ming; Haaland, Benjamin.
In: Prostate, Vol. 77, No. 6, 01.05.2017, p. 639-646.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer
T2 - Prostate
AU - Chopra,Akhil
AU - Georgieva,Mina
AU - Lopes,Gilberto
AU - Yeo,Chong Ming
AU - Haaland,Benjamin
PY - 2017/5/1
Y1 - 2017/5/1
N2 - BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.
AB - BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.
KW - abiraterone
KW - advanced prostate cancer
KW - castrate-resistant
KW - enzalutamide
UR - http://www.scopus.com/inward/record.url?scp=85015436737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015436737&partnerID=8YFLogxK
U2 - 10.1002/pros.23309
DO - 10.1002/pros.23309
M3 - Article
VL - 77
SP - 639
EP - 646
JO - Prostate
JF - Prostate
SN - 0270-4137
IS - 6
ER -